Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An Author's Perspective
    • Ask the Experts
    • Bioanalysis articles
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Spotlights
    • Tech Digest
    • T&F journals

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Awareness
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Professional development
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

The technology behind Bio-Rad’s custom recombinant antibodies

25 Oct 2017
Antibodies | ADCs

Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.


For more information on Bio-Rad, please click here.

Top content

  • A loaded tip
  • Unlocking the inner workings of cancer cells
  • Jessica Bridges Weaver named as a 2026 Women in Business award winner

Related tags

antibody Bio-rad biotherapeutics technology
Previous article

Related articles

10 JUN 2014 GENERAL INTEREST
Agreement enables automated protein quantitation
7 SEP 2015 DRUG DEVELOPMENT
Recommendations for the development and validation of confirmatory anti-drug antibody assays
12 JUN 2014 JOURNAL ARTICLES
Addressing matrix effects in ligand-binding assays through the use of new reagents and technology
14 NOV 2013 COLLABORATIONS AND MERGERS
Rheumatoid arthritis biomarker collaboration
24 MAR 2016 AUTOMATION
Validation of an integrated series of ligand-binding assays for the quantitative determination of antibody–drug conjugates in biological matrices
23 DEC 2015 CHROMATOGRAPHY
16th Annual Land O’Lakes Bioanalytical Conference
  • About
  • Accessibility
  • Advertising & Sponsorship
  • Contact Us
  • Editorial Policies
  • Permissions
  • Whitelist Emails
  • Zone Leaders

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone